**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 73197

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Cohort Study***

**Incidental gallbladder cancer diagnosis confers survival advantage irrespective of tumour stage and characteristics**

Alarabiyat M *et al.* IGBC survival advantage compared to NIGBC

Moath Alarabiyat, Syed Soulat Raza, John Isaac, Darius Mirza, Ravi Marudanayagam, Keith Roberts, Manuel Abradelo, David C Bartlett, Bobby V Dasari, Robert P Sutcliffe, Nikolaos A Chatzizacharias

**Moath Alarabiyat, Syed Soulat Raza, John Isaac, Darius Mirza, Ravi Marudanayagam, Keith Roberts, Manuel Abradelo, David C Bartlett, Bobby V Dasari, Robert P Sutcliffe,** HPB and Liver Transplant Unit, Queen Elizabeth Hospital, Birmingham B15 2GW, United Kingdom

**Nikolaos A Chatzizacharias,** Department of HPB and Liver Transplantation, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham B15 2TH, United Kingdom

**Author contributions:** Alarabiyat M and Raza SS are responsible for the data collection, statistical analysis, and wrote the manuscript; Alarabiyat M did the statistical analysis; Isaac J, Mirza DF, Marudanayagam R, Roberts K, Abradelo M, Bartlett DC, Dasari B, Sutcliffe BP are responsible for interpretation of data, manuscript revision and editing, approval of finalized version of the manuscript; Chatzizacharias N is responsible for developed research concept, writing, manuscript preparation, editing and review.

**Corresponding author: Nikolaos A Chatzizacharias, FACS, FRCS, MD, PhD, Surgeon,** Department of HPB and Liver Transplantation, Queen Elizabeth Hospital, University Hospitals Birmingham, Third Floor, Nuffield House, Mindelsohn Way, Birmingham B15 2TH, United Kingdom. chatzizacharias@gmail.com

**Received:** November 13, 2021

**Revised:** January 22, 2022

**Accepted: March 26, 2022**

**Published online:**

**Abstract**

BACKGROUND

Incidental gallbladder cancer (IGBC) represents 50%-60% of gallbladder cancer cases. Data are conflicting on the role of IGBC diagnosis in oncological outcomes. Some studies suggest that IGBC diagnosis does not affect outcomes, while others that overall survival (OS) is longer in these cases compared to non-incidental diagnosis (NIGBC). Furthermore, some studies reported early tumour stages and histopathologic characteristics as possible confounders, while others not.

AIM

To investigate the role of IGBC diagnosis on patients’ overall survival, especially after surgical treatment with curative intent.

METHODS

Retrospective analysis of all patient referrals with gallbladder cancer between 2008 and 2020 in a tertiary hepatobiliary centre. Statistical comparison of patient and tumour characteristics between IGBC and NIGBC subgroups was performed. Survival analysis for the whole cohort, surgical and non-surgical subgroups was done with the Kaplan-Meier method and the use of log rank test. Risk analysis was performed with univariable and multivariable Cox regression analysis.

RESULTS

The cohort included 261 patients with gallbladder cancer. 65% of cases had NIGBC and 35% had IGBC. A total of 90 patients received surgical treatment (66% of IGBC cases and 19% of NIGBC cases). NIGBC patients had more advanced T stage and required more extensive resections than IGBC ones. OS was longer in patients with IGBC in the whole cohort (29 *vs* 4 mo, *P* < 0.001), as well as in the non-surgical (14 *vs* 2 mo, *P* < 0.001) and surgical subgroups (29 *vs* 16.5 mo, *P* = 0.001). Disease free survival (DFS) after surgery was longer in patients with IGBC (21.5 mo *vs* 8.5 mo, *P* = 0.007). N stage and resection margin status were identified as independent predictors of OS and DFS. NIGBC diagnosis was identified as an independent predictor of OS.

CONCLUSION

IGBC diagnosis may confer a survival advantage independently of the pathological stage and tumour characteristics. Prospective studies are required to further investigate this, including detailed pathological analysis and molecular gene expression.

**Key Words:** Gallbladder cancer; Incidental gallbladder cancer; Non-incidental gallbladder cancer; Gallbladder cancer survival

Alarabiyat M, Raza SS, Isaac J, Mirza D, Marudanayagam R, Roberts K, Abradelo M, Bartlett DC, Dasari B, Sutcliffe R, Chatzizacharias NA. Incidental gallbladder cancer diagnosis confers survival advantage irrespective of tumour stage and characteristics. *World J Gastroenterol* 2022; In press

**Core Tip:** Data are conflicting on the role of incidental gallbladder cancer (IGBC) diagnosis in oncological outcomes. Some studies suggest that IGBC diagnosis does not affect outcomes, while others that overall survival (OS) is longer in these cases compared to non-incidental diagnosis (NIGBC). In our study, IGBC diagnosis conferred better OS in all patients with gallbladder cancer, as well as within the surgical and non-surgical groups. Similarly, disease free survival was significantly longer in patients with IGBC. NIGBC diagnosis was identified as an independent predictor of OS along with N stage and resection margin status.

**INTRODUCTION**

Gallbladder cancer (GBC) is associated with poor prognosis even after treatment, with median overall survival (OS) ranging in the literature between 3 and 22 mo[1,2]. Incidental gallbladder cancer (IGBC) discovered on routine histological examination of gallbladder specimens after cholecystectomy is more common than non-incidental gallbladder cancer (NIGBC) and represents 50%-60% of all cases[3-5]. The prognostic implication of incidental or non-incidental diagnosis in oncological outcomes is still a matter of debate as is the effect of the timing of curative intent resection which is performed as a secondary operation in IGBC.

Published evidence are contradictory with some studies suggesting that incidental diagnosis does not affect survival[5-8], while others showed longer survival with IGBC[9-11]. Earlier tumour stages in the IGBC group have been suggested as a confounding factor for any potential survival benefit[5]. On the contrary, other studies identified a survival benefit in IGBC even after controlling for tumour stage and degree of differentiation[9,10].

The aim of this study was to investigate the role of IGBC diagnosis in patient OS and especially after surgical treatment with curative intent.

**MATERIALS AND METHODS**

This is a retrospective single tertiary centre cohort study between January 2008 and December 2020. The sample included all patients with a histological diagnosis of GBC obtained by surgery or biopsy. The management of all patients was discussed and agreed in the hepatobiliary multidisciplinary (MDT) meeting. IGBC diagnosis was established after histopathological examination of specimens following cholecystectomy for benign aetiology. This was followed by complete staging with a computerized tomography scan of the thorax, abdomen and pelvis (CT-TAP) with subsequent curative intent resection if appropriate. NIGBC diagnosis was made based on imaging and/or biopsy after MDT discussion of referred patients. All patients had staging with CT-TAP, followed by surgery if clinically appropriate. In patients with locally advanced disease, neoadjuvant chemotherapy was administered and resection was contemplated after restaging. Liver magnetic resonance imaging and positron emission tomography scans were used selectively in both groups if liver metastases or extrahepatic disease was suspected on CT. Following surgical resection all patients were referred to oncology for assessment of adjuvant chemotherapy (AC).

Data were collected and recorded for patient's demographics, American society of anesthesiology (ASA) score, extent of surgical resection, histology, chemotherapy, recurrence and survival. The extent of surgery was defined as minor if radical cholecystectomy, gallbladder (GB) bed resection or liver segments IVb/V resection with or without bile duct resection was performed. It also included patients who only had bile duct resection. The resection was defined as major if a major hepatectomy (three or more liver segments) or multi-visceral resection was performed. Recurrence was defined as local/regional (GB bed, hilar lymph nodes), distant or both. The primary outcome of the study was difference in OS between IGBC and NIGBC and the secondary outcome was difference in disease-free survival (DFS).

*T*-test, Chi-Square, Fisher’s Exact and Mann-Whitney U tests were used as appropriate to compare variables and outcomes between the two groups, with statistical significance set at *P* < 0.05. Survival analysis was performed with the Kaplan-Meier method and log rank test was used to compare survival curves between the study groups. Univariable and multivariable time to event analyses were performed using the Cox proportional hazard model to determine risk factors for OS and DFS. Variables were subjected to a univariable analysis first and those with *P* < 0.2 were introduced into a multivariable model. Hazard ratios (HR) and associated 95% confidence intervals (CI) were calculated. A two-tailed *P* value < 0.05 was considered statistically significant. All statistical analyses were performed using the software package SPSS Statistics for Windows (version 25.0; SPSS Inc., Chicago, IL, United States).

**RESULTS**

***Cohort characteristics and management pathway***

The study cohort comprised of 261 patients, with 35% presenting as IGBC and 65% had non incidental presentation (NIGBC) at the time of diagnosis (Figure 1). Median age was 69 years [interquartile range (IQR) 61-77] and male to female ratio was 1:3. Eighty-one percent of NIGBC and 34% of IGBC patients did not undergo resection. For the majority of these (82%) locally advanced or metastatic disease was the main reason. Other causes included patient’s choice, poor medical status and pathological stage < 1b (where resection is not indicated) (Table 1). Reasons for not having AC after resection were patients’ choice or comorbidities and early tumour stages (CIS, T1/T2, N0) with negative resection margins.

***Patient and tumour characteristics of surgical patients***

A total of 90 patients had curative intent resection. The type of resection depended on IGBC *vs* NIGBC diagnosis, pre-operative staging, intra-operative findings, cystic duct margin status and the T stage of IGBC patients. Hepatoduodenal (portal) lymphadenectomy was performed in all patients. For IGBC cases, the median time from the time of the index cholecystectomy to the curative resection was 13.5 wk (IQR: 11-16 wk).

Patient and tumour characteristics are shown on Table 2. Patients with NIGBC had more advanced T stage and underwent more extensive resections compared to those with IGBC. Similarly, N stage approached but did not reach significance. The types of procedures performed are shown on Table 3.

***Survival analysis***

For the whole cohort, median OS was longer in patients with IGBC diagnosis, (29 *vs* 4 mo, *P* < 0.001). OS of IGBC patients was significantly longer compared to NIGBC patients in the non-surgical group (14 *vs* 2 mo, *P* < 0.001), as well as the surgical group (29 *vs* 16.5 mo, *P* = 0.001). Similarly, DFS was significantly longer in patients with IGBC (21.5 mo *vs* 8.5 mo, *P* = 0.007) (Figure 2).

***Risk analysis***

Univariable Cox regression analysis (Table 4) identified that age, ASA, T stage, N stage, resection margin status and NIGBC diagnosis were significantly related to OS (*P* < 0.05). On multivariable analysis, N stage, resection margin status and NIGBC diagnosis were identified as independent predictors of survival, increasing the risk of mortality by 3, 5 and 2 times respectively (Table 4).

Similarly, T stage, N stage, resection margin status and NIGBC diagnosis were identified to be associated with worse DFS on univariable analysis, however only N stage and resection margin status were found to be independent predictors on multivariable analysis (Table 5).

In an effort to statistically investigate if NIGBC diagnosis acted as a confounding factor for the T stage of the disease despite the use of time-dependent regression analysis, models without this parameter were produced. Again, only N stage and margin status were identified as independent prognostic factors for OS and DFS, while T stage was not (Tables 4 and 5).

**DISCUSSION**

GBC is a rare malignancy with unfavorable prognosis despite the advances in oncological treatments[1,2,12]. The timing of GBC diagnosis, whether incidental after cholecystectomy for benign causes or pre-operative on imaging and/or biopsy, has been previously under investigation for the potential effect in outcomes, however evidence is scarce. Violation of the anatomical planes around the tumour and incomplete clearance during the index laparoscopic cholecystectomy with residual disease in 35%-46% of the patients have been proposed as factors responsible for adverse oncological outcomes in IGBC patients[13-15]. Furthermore, inadvertent GB perforation during cholecystectomy has been reported in up to 22%[16,17], and this could theoretically lead to tumour seeding and metastatic disease. Interestingly, the site of invasion of local disease has also been shown to play an important role in T2 disease[15]. Nonetheless, some published evidence suggested that IGBC diagnosis confers favourable survival, regardless of the stage or degree of differentiation of the disease[9,11]. On the other hand, in other studies, NIGBC diagnosis did not adversely affect survival[5-8]. In a meta-analysis of 51 studies by Pyo *et al*[18], IGBC patients had favorable survival in comparison to NIGBC. However, not all studies included in this meta-analysis were able to show the same difference between both groups.

Sixty five percent of referred patients in our cohort had a preoperative radiological diagnosis of GBC. Sixty six percent of all patients did not proceed to an oncological resection (81% of NIGBC and 36% of IGBC patients), 16% of these due to locally advanced disease (all NIGBC patients) and 38% due to metastatic disease on staging imaging (23% of IGBC and 46% of NIGBC patients). Only 3% of IGBC were stage T1a or below and therefore, no further resection was indicated. Of note only 7% of patients were deemed unfit for surgical treatment. It is clear that the majority of the patients that did not proceed to management with curative intent were due to the late presentation of the disease, a fact that is well described for GBC[19]. The percentage of patients who had AC after curative intent surgery was low (22%). This is comparable with the published literature of around 24%[20]. The reasons for this may include patients’ choice and comorbidities, however, may also be attributed to the change in recommended best practice over the years of the study. According to a previously published expert consensus statement, AC was considered only in patients with high risk pathologic features: T3-T4 stages, metastatic lymph nodes and positive resection margins[21]. However, after the BILCAP trial showing improved survival with capecitabine (36.4 mo to 51.1 mo; *P* = 0.028), it is currently recommended that all patients with resected biliary tract malignancy, including GB cancer, receive 6 mo of adjuvant capecitabine[22]. The results of the currently ongoing ACTICCA-1 trial are eagerly awaited and will provide further evidence if the combination chemotherapy of gemcitabine and cisplatin is superior to capecitabine monotherapy in the adjuvant setting.

Our data suggests that NIGBC diagnosis adversely affected oncological outcomes. NIGBC patients were more likely to have higher stages of the disease (T3/4), consequently undergoing more extensive resections. The range of oncological procedures for selected cases included multi-visceral resections and major hepatectomies to achieve histologically clear resection margins. Routine performance of such procedures is not associated with survival benefit and has high morbidity rates; however, it is still indicated when the vascular inflow or resection margins are/may be compromised[23-25]**.** Positive lymph node status was more common in patients with NIGBC with the difference approaching statistical significance. OS of all patients with NIGBC diagnosis was substantially worse than those with IGBC and this was also noted in both surgical and non-surgical subgroups. Furthermore, in the surgical subgroup, NIGBC diagnosis was identified as an independent predictor of OS; doubling the risk of mortality. Stronger predictors were pN stage and margin status, increasing the risk by 3 and 5 times respectively. These findings persisted when models computed that accounted for the possibility of NIGBC diagnosis acting as a confounding factor for T stage (by not including this parameter in the analysis), indicating that it is not true. This seemingly paradoxical observation may be explained by the presence of micro-metastases in early stages of GBC [26], which would affect and in the end dictate OS and DFS, rather than pT stage. Similar were the results for DFS, with N stage and margin status conferring higher relative risk of recurrence, while NIGBC diagnosis approached but did not reach significance.

Lymph node status is an important prognostic factor in GBC. Widmann *et al*[27] in a meta-analysis of 18 observational studies which included more than 27000 patients, has shown that lymph node involvement has significant effect on OS and DFS. Lymphadenectomy also was associated with better OS and DFS in patients with T1b, T2 and T3 disease. This was not clearly demonstrated with T4 disease due to the low number of cases undergoing curative resection in this stage. Lymph node micrometastases, defined as disease detected on immune-histochemical staining, have also been described to correlate with the pathologic N stage of the disease and disease prognosis[28]. Nonetheless, the significance of the extent of lymphadenectomy and lymph node yield is controversial in the published literature, with data from two studies suggesting that harvesting more than four lymph nodes during surgery is associated with improved survival[29,30], whilst a third study concluded that lymph node yield does not correlate with improved survival[31]. These differences may be explained by the differences in pathological reporting (higher lymph node yield may result in more accurate pN staging) and/or variations in the non-surgical part of the patients’ management, such differences in the administration of neoadjuvant and adjuvant chemotherapy, regimens, duration *etc.*

Overall, our data suggest that the timing of diagnosis of GBC may play a significant role in the oncological outcomes. Due to the retrospective nature of the study and the long study period, data on the site of invasion (hepatic *vs* peritoneal) were not available, hence this could not be investigated as a possible explanation[32,33]. Another possibility is a difference in the genetic profile of the tumours which could account for different behavior, such as early micrometastases, that cannot be captured by the common radiological investigations and standard pathological parameters of stage and differentiation [34]. However, this cannot be investigated by the current study and would require a prospective molecular study design.

The limitations of the study include its single centre retrospective methodology. The long study period also included differences and evolution in the surgical approach during the oncological resection, with more bile duct resections done during the early study period to achieve a negative margin and a greater lymph node yield. In the later years, bile duct resection was only performed in the presence of a positive cystic duct margin. Nonetheless, this is the first study to include all patients referred for GBC to a tertiary regional centre, rather than only the ones receiving surgical treatment, therefore providing outcome data in an intention to treat basis over the whole referral cohort including the patients that did not receive surgical treatment. It is also one of few studies to demonstrate the effect of non-incidental diagnosis on the oncological outcomes.

**CONCLUSION**

Conclusively, the presented data suggest that IGBC diagnosis may confer a survival advantage, including patients that received surgical treatment, independently of the pathological stage and tumour characteristics. Prospective studies are required to investigate the reasons behind this, including detailed pathological analysis and molecular gene expression.

**ARTICLE HIGHLIGHTS**

***Research background***

Incidental gallbladder cancer (IGBC) represents 50%-60% of gallbladder cancer cases. Data are conflicting on the role of IGBC diagnosis in oncological outcomes. Some studies suggest that IGBC diagnosis does not affect outcomes, while others that overall survival (OS) is longer in these cases compared to non-incidental diagnosis (NIGBC). Furthermore, some studies reported early tumour stages and histopathologic characteristics as possible confounders, while others not.

***Research motivation***

GB cancer is an uncommon malignancy with poor survival. Data suggest whether the diagnosis is incidental or not may play a role in the oncological outcomes. Confirmation of this observation may lead in further research aiming to better identify the reasons and refining the treatment strategy based on the presenting diagnosis.

***Research objectives***

This study aimed to investigate the role of IGBC diagnosis on patients’ overall survival, especially after surgical treatment with curative intent.

***Research methods***

This is a retrospective analysis of all patient referrals with gallbladder cancer between 2008 and 2020 in a tertiary hepatobiliary centre. All patients had complete staging and were discussed in the multidisciplinary meeting prior to deciding on the treatment plan. Demographic, surgical and tumour variables were collected and compared between patients with IGBC and NIGBC using the appropriate statistical tests. Survival curves for OS and DFS were created using Kaplan-Meier method and compared with the log rank test. Risk analysis for independent predictors of OS and DFS was performed with univariable time to event analysis using the Cox proportional hazard model. Factors with a *P* value of < 0.200 were entered into a multivariable model and independent predictors (those with *P* < 0.05) were indentified. All statistical analysis was done using the software SPSS for Windows (Version 25.0, SPSS Inc., Chicago, IL, United States).

***Research results***

261 patients with GB cancer were included. Almost one-third pf patients had IGBC (91/261 patients) and two-thirds had NIGC. A total of 90/261 (34%) patients proceeded to have oncological resection. Metastatic disease was the most common reason for not having oncological resection. Patients with NIGBC were more likely to have advanced T stages of the disease and required more extensive resections than patients with IGBC. Survival analysis shows that patients with IGBC had better OS than patients with NIGBC in the whole cohort (29 *vs* 4 mo, *P* < 0.001), as well as in the non-surgical (14 *vs* 2 mo, *P* < 0.001) and surgical subgroups (29 *vs* 16.5 mo, *P* = 0.001). DFS was similarly better in patients with IGBC who underwent oncological resection (21.5 mo *vs* 8.5 mo, *P* = 0.007). After univariable and multivariable risk analysis, N stage, resection margin status and non-incidental diagnosis were identified as independent predictors of OS. N stage and resection margin status were also independent predictors of DFS. Within the limitations of a retrospective single centre study, our data suggest that difference in the oncological outcomes between the two groups cannot be solely explained by differences in pathologic or tumour features.

***Research conclusions***

Our study suggests that IGBC diagnosis may confer a survival advantage, including patients that received surgical treatment, independently of the pathological stage and tumour characteristics. Prospective studies are required to investigate the reasons behind this, including detailed pathological analysis and molecular gene expression.

***Research perspectives***

Published evidence is still contradicting. The theory that IGBC and NIGBC are two distinct variants of the same disease remains to be proven by detailed pathologic assessment and research in cancer molecular genetics.

**REFERENCES**

1 **Jaruvongvanich V**, Yang JD, Peeraphatdit T, Roberts LR. The incidence rates and survival of gallbladder cancer in the USA. *Eur J Cancer Prev* 2019; **28**: 1-9 [PMID: 28683010 DOI: 10.1097/CEJ.0000000000000402]

2 **Chen C**, Geng Z, Shen H, Song H, Zhao Y, Zhang G, Li W, Ma L, Wang L. Long-Term Outcomes and Prognostic Factors in Advanced Gallbladder Cancer: Focus on the Advanced T Stage. *PLoS One* 2016; **11**: e0166361 [PMID: 27846279 DOI: 10.1371/journal.pone.0166361]

3 **Shih SP**, Schulick RD, Cameron JL, Lillemoe KD, Pitt HA, Choti MA, Campbell KA, Yeo CJ, Talamini MA. Gallbladder cancer: the role of laparoscopy and radical resection. *Ann Surg* 2007; **245**: 893-901 [PMID: 17522515 DOI: 10.1097/SLA.0b013e31806beec2]

4 **Duffy A**, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y, D'Angelica M, Dematteo RP, Blumgart LH, O'Reilly EM. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). *J Surg Oncol* 2008; **98**: 485-489 [PMID: 18802958 DOI: 10.1002/jso.21141]

5 **Löhe F**, Meimarakis G, Schauer C, Angele M, Jauch KW, Schauer RJ. The time of diagnosis impacts surgical management but not the outcome of patients with gallbladder carcinoma. *Eur J Med Res* 2009; **14**: 345-351 [PMID: 19666394 DOI: 10.1186/2047-783x-14-8-345]

6 **Fong Y**, Jarnagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. *Ann Surg* 2000; **232**: 557-569 [PMID: 10998654 DOI: 10.1097/00000658-200010000-00011]

7 **Yip VS**, Gomez D, Brown S, Byrne C, White D, Fenwick SW, Poston GJ, Malik HZ. Management of incidental and suspicious gallbladder cancer: focus on early referral to a tertiary centre. *HPB (Oxford)* 2014; **16**: 641-647 [PMID: 24279377 DOI: 10.1111/hpb.12189]

8 **Cavallaro A,** Piccolo G, Di Vita M, Zanghì A, Cardì F, Di Mattia P, Barbera G, Borzì L, Panebianco V, Di Carlo I, Cavallaro M, Cappellani A. Managing the incidentally detected gallbladder cancer: algorithms and controversies. *Int J Surg* 2014; **12 Suppl 2**: S108-S119 [PMID 25182380 DOI: 10.1016/j.ijsu.2014.08.367]

9 **Mazer LM,** Losada HF, Chaudhry RM, Velazquez-Ramirez GA, Donohue JH, Kooby DA, Nagorney DM, Adsay NV, Sarmiento JM. Tumour characteristics and survival analysis of incidental *vs* suspected gallbladder carcinoma. *J Gastrointest Surg* 2012; **16**: 1311-1317 [PMID 22570074 DOI:10.1007/s11605-012-1901-y]

10 **Cha BH,** Bae JM. Comparison of clinical outcomes of incidental and non- incidental gallbladder cancers: a single-centre cross- sectional study. *Asian Pac J Cancer Prev* 2014; **15**: 1281-1283 [PMID 24606453 DOI:10.7314/apjcp.2014.15.3.1281]

11 **Ethun CG**, Le N, Lopez-Aguiar AG, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Russell MC, Maithel SK. Pathologic and Prognostic Implications of Incidental *versus* Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. *Am Surg* 2017; **83**: 679-686 [PMID: 28738935 DOI: 10.1177/000313481708300721]

12 **Bacalbasa N,** Balescu I, Dima S and Popescu I. Surgical Advances in the Treatment of Gallbladder Carcinoma at Different Stages, Bile Duct Cancer, Luis Rodrigo, IntechOpen, 2019 [DOI: 10.5772/intechopen.84154]

13 **Pawlik TM**, Gleisner AL, Vigano L, Kooby DA, Bauer TW, Frilling A, Adams RB, Staley CA, Trindade EN, Schulick RD, Choti MA, Capussotti L. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. *J Gastrointest Surg* 2007; **11**: 1478-86; discussion 1486-1487 [PMID: 17846848 DOI: 10.1007/s11605-007-0309-6]

14 **de Savornin Lohman EAJ**, van der Geest LG, de Bitter TJJ, Nagtegaal ID, van Laarhoven CJHM, van den Boezem P, van der Post CS, de Reuver PR. Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease. *Ann Surg Oncol* 2020; **27**: 1132-1142 [PMID: 31741109 DOI: 10.1245/s10434-019-08074-4]

15 **Vega EA**, Vinuela E, Okuno M, Joechle K, Sanhueza M, Diaz C, Jarufe N, Martinez J, Troncoso A, Diaz A, Chun YS, Tzeng CD, Lee JE, Vauthey JN, Conrad C. Incidental *vs* non-incidental gallbladder cancer: index cholecystectomy before oncologic re-resection negatively impacts survival in T2b tumors. *HPB (Oxford)* 2019; **21**: 1046-1056 [PMID: 30711243 DOI: 10.1016/j.hpb.2018.12.006]

16 **Goetze TO**, Paolucci V. Use of retrieval bags in incidental gallbladder cancer cases. *World J Surg* 2009; **33**: 2161-2165 [PMID: 19636610 DOI: 10.1007/s00268-009-0163-7]

17 **Lee HY**, Kim YH, Jung GJ, Roh YH, Park SY, Kang NU, Yoon SH, Cho JH, Roh MH, Han SY, Lee SW, Baek YH, Jeong JS. Prognostic factors for gallbladder cancer in the laparoscopy era. *J Korean Surg Soc* 2012; **83**: 227-236 [PMID: 23091795 DOI: 10.4174/jkss.2012.83.4.227]

18 **Pyo JS**, Son BK, Lee HY, Oh IW, Chung KH. Incidental Carcinoma after Cholecystectomy for Benign Disease of the Gallbladder: A Meta-Analysis. *J Clin Med* 2020; **9** [PMID: 32423156 DOI: 10.3390/jcm9051484]

19 **Andrén-Sandberg A**. Diagnosis and management of gallbladder cancer. *N Am J Med Sci* 2012; **4**: 293-299 [PMID 22866265 DOI:10.4103/1947-2714.98586]

20 **Kemp Bohan PM**, Kirby DT, Chick RC, Bader JO, Clifton GT, Vreeland TJ, Nelson DW. Adjuvant Chemotherapy in Resectable Gallbladder Cancer is Underutilized Despite Benefits in Node-Positive Patients. *Ann Surg Oncol* 2021; **28**: 1466-1480 [PMID: 32749621 DOI: 10.1245/s10434-020-08973-x]

21 **Aloia TA**, Járufe N, Javle M, Maithel SK, Roa JC, Adsay V, Coimbra FJ, Jarnagin WR. Gallbladder cancer: expert consensus statement. *HPB (Oxford)* 2015; **17**: 681-690 [PMID: 26172135 DOI: 10.1111/hpb.12444]

22 **Shroff RT**, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. *J Clin Oncol* 2019; **37**: 1015-1027 [PMID: 30856044 DOI: 10.1200/JCO.18.02178]

23 **D'Angelica M**, Dalal KM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Analysis of the extent of resection for adenocarcinoma of the gallbladder. *Ann Surg Oncol* 2009; **16**: 806-816 [PMID: 18985272 DOI: 10.1245/s10434-008-0189-3]

24 **Araida T**, Higuchi R, Hamano M, Kodera Y, Takeshita N, Ota T, Yoshikawa T, Yamamoto M, Takasaki K. Hepatic resection in 485 R0 pT2 and pT3 cases of advanced carcinoma of the gallbladder: results of a Japanese Society of Biliary Surgery survey--a multicenter study. *J Hepatobiliary Pancreat Surg* 2009; **16**: 204-215 [PMID: 19219399 DOI: 10.1007/s00534-009-0044-3]

25 **D'Souza MA**, Valdimarsson VT, Campagnaro T, Cauchy F, Chatzizacharias NA, D'Hondt M, Dasari B, Ferrero A, Franken LC, Fusai G, Guglielmi A, Hagendoorn J, Hidalgo Salinas C, Hoogwater FJH, Jorba R, Karanjia N, Knoefel WT, Kron P, Lahiri R, Langella S, Le Roy B, Lehwald-Tywuschik N, Lesurtel M, Li J, Lodge JPA, Martinou E, Molenaar IQ, Nikov A, Poves I, Rassam F, Russolillo N, Soubrane O, Stättner S, van Dam RM, van Gulik TM, Serrablo A, Gallagher TM, Sturesson C; E-AHPBA scientific and research committee. Hepatopancreatoduodenectomy -a controversial treatment for bile duct and gallbladder cancer from a European perspective. *HPB (Oxford)* 2020; **22**: 1339-1348 [PMID: 31899044 DOI: 10.1016/j.hpb.2019.12.008]

26 **Endo I**, Shimada H, Takimoto A, Fujii Y, Miura Y, Sugita M, Morioka D, Masunari H, Tanaka K, Sekido H, Togo S. Microscopic liver metastasis: prognostic factor for patients with pT2 gallbladder carcinoma. *World J Surg* 2004; **28**: 692-696 [PMID: 15175901 DOI: 10.1007/s00268-004-7289-4]

27 **Widmann B**, Warschkow R, Beutner U, Weitzendorfer M, Ukegjini K, Schmied BM, Tarantino I, Steffen T. Effect of lymphadenectomy in curative gallbladder cancer treatment: a systematic review and meta-analysis. *Langenbecks Arch Surg* 2020; **405**: 573-584 [PMID: 32458141 DOI: 10.1007/s00423-020-01878-z]

28 **Tanabe M**, Endo I, Masunari H, Sugita M, Morioka D, Ishikawa T, Ichikawa Y, Shimada H. Is lymph-node micrometastasis in gallbladder cancer a significant prognostic factor? *Hepatogastroenterology* 2012; **59**: 31-35 [PMID: 22251520 DOI: 10.5754/hge10010]

29 **Ito H**, Ito K, D'Angelica M, Gonen M, Klimstra D, Allen P, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. *Ann Surg* 2011; **254**: 320-325 [PMID: 21617582 DOI: 10.1097/SLA.0b013e31822238d8]

30 **Tran TB**, Nissen NN. Surgery for gallbladder cancer in the US: a need for greater lymph node clearance. *J Gastrointest Oncol* 2015; **6**: 452-458 [PMID: 26487937 DOI: 10.3978/j.issn.2078-6891.2015.062]

31 **Ong SL**, Garcea G, Thomasset SC, Neal CP, Lloyd DM, Berry DP, Dennison AR. Ten-year experience in the management of gallbladder cancer from a single hepatobiliary and pancreatic centre with review of the literature. *HPB (Oxford)* 2008; **10**: 446-458 [PMID: 19088932 DOI: 10.1080/13651820802392346]

32 **Lee W,** Jeong CY, Jang JY, Kim YH, Roh YH, Kim KW, Kang SH, Yoon MH, Seo HI, Yun SP, Park JI, Jung BH, Shin DH, Choi YI, Moon HH, Chu CW, Ryu JH, Yang K, Park YM, Hong SC. Do hepatic-sided tumours require more extensive resection than peritoneal-sided tumours in patients with T2 gallbladder cancer? Results of a retrospective multicentre study. *Surgery* 2017; **162**: 515-524 [PMID 28629653 DOI: 10.1016/j.surg.2017.05.004]

33 **Lee H**, Choi DW, Park JY, Youn S, Kwon W, Heo JS, Choi SH, Jang KT. Surgical Strategy for T2 Gallbladder Cancer According to Tumor Location. *Ann Surg Oncol* 2015; **22**: 2779-2786 [PMID: 25519930 DOI: 10.1245/s10434-014-4300-7]

34 **Wardell CP**, Fujita M, Yamada T, Simbolo M, Fassan M, Karlic R, Polak P, Kim J, Hatanaka Y, Maejima K, Lawlor RT, Nakanishi Y, Mitsuhashi T, Fujimoto A, Furuta M, Ruzzenente A, Conci S, Oosawa A, Sasaki-Oku A, Nakano K, Tanaka H, Yamamoto Y, Michiaki K, Kawakami Y, Aikata H, Ueno M, Hayami S, Gotoh K, Ariizumi SI, Yamamoto M, Yamaue H, Chayama K, Miyano S, Getz G, Scarpa A, Hirano S, Nakamura T, Nakagawa H. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. *J Hepatol* 2018; **68**: 959-969 [PMID: 29360550 DOI: 10.1016/j.jhep.2018.01.009]

**Footnotes**

**Institutional review board statement:** The study was approved by the departmental ethics committee.

**Informed consent statement:** As this was an anonymised retrospective cohort study over a period of 12 years, individual consent forms were not required based on the policy of Queen Elizabeth Hospital and the UK on ethics and research.

**Conflict-of-interest statement:** The authors have no conflicts of interest to disclose.

**Data sharing statement:** The original dataset is anonymized and available upon request from the corresponding author at Nikolaos.chatzizacharias@uhb.nhs.net.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 13, 2021

**First decision:** January 9, 2022

**Article in press:**

**Specialty type:** Surgery

**Country/Territory of origin:** United Kingdom

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Aktas S, Turkey; Garg PK, India; Kai K, Japan; Yasukawa K, Japan **S-Editor:** Wu YXJ **L-Editor:** A **P-Editor:** Wu YXJ

**Figure Legends**



**Figure 1 Management pathways of whole cohort.**



**Figure 2 Kaplan Meier survival curves for incidental gallbladder cancer *vs* non-incidental gallbladder cancer.** A: Overall survival (OS) of all cohort; B: Overall survival (OS) of non-surgical treatment; C: OS for surgical treatment; D: Disease-free survival for surgical treatment. IGBC: Incidental gallbladder cancer; NIGBC: Non-incidental gallbladder cancer.

**Table 1 Reasons for not proceeding with oncological resection, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Reason** | **IGBC (*n* = 33, 19%)** | **NIGBC (*n* = 138, 81%)** | **Total number (*n* = 171)1** |
| Locally advanced inoperable disease | 0 | 41 (30) | 41 (24) |
| Metastatic disease | 21 (64) | 78 (56) | 99 (58) |
| Patient declined surgery | 5 (15) | 3 (2) | 8 (5) |
| Unfit for surgery | 4 (12) | 15 (11) | 19 (11) |
| Surgery not required | 3 (9) | 0 | 3 (2) |

1Data missing for one patient.

**Table 2 Patient and tumour characteristics for the surgical group, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **IGBC (*n* = 58)** | **NIGBC (*n* = 32)** | ***P* value** |
| Median age (range) | 63 yr (55.8-71.3) | 66 yr (66.0-71.5) | 0.302 |
| Gender |  |  | 0.08 |
| Male | 9 (16) | 10 (32) |
| Female | 49 (84) | 22 (68) |
| Ethnicity |  |  | 0.507 |
| Caucasian | 39 (67) | 23 (72) |
| Asian | 15 (26) | 5 (16) |
| Black | 3 (5) | 2 (6) |
| Missing | 1 (2) | 2 (6) |
| Median BMI (range) | 28.2 (24.3-32.1) | 28.2 (24.2-30.7) | 0.563 |
| ASA score |  |  | 0.829 |
| 1 | 4 (7) | 2 (6) |
| 2 | 43 (74) | 23 (72) |
| 3 | 10 (17) | 6 (19) |
| Missing | 1 (2) | 1 (3) |
| Median CCI (range) | 4 (3-5) | 4 (4-6) | 0.635 |
| Extent of surgery |  |  | **< 0.001** |
| Minor resection | 57 (98) | 24 (75) |
| Major resection | 1 (2) | 8 (25) |
| T stage |  |  | **< 0.001** |
| CIS | 1 (2) | 1 (3) |
| T1a | 3 (5) | 0 |
| T1b | 4 (7) | 1 (3) |
| T2 | 42 (72) | 12 (38) |
| T3 | 7 (12) | 15 (47) |
| T4 | 1 (2) | 3 (9) |
| N status |  |  | 0.051 |
| N0 | 41 (71) | 16 (50) |
| N1/2 | 17 (29) | 16 (50) |
| Histologic type |  |  | 0.746 |
| CIS | 1 (2) | 1 (3) |
| Adenocarcinoma | 55 (94) | 30 (94) |
| Adeno-squamous | 1 (2) | 1 (3) |
| Mixed | 1 (2) | 0 |
| Degree of differentiation (CIS excluded) |  |  | 0.614 |
| Well | 7 (12) | 4 (13) |
| Moderate | 30 (52) | 20 (63) |
| Poor | 12 (21) | 5 (16) |
| Undifferentiated/unclassified | 8 (14) | 2 (6) |
| Resection margin |  |  | 0.169 |
| Negative | 53 (91) | 26 (81) |
| Positive | 5 (9) | 6 (19) |
| Cystic duct margin on index cholecystectomy | 6 (10) | N/A | N/A |
| Post-operative complications | 15 (26) | 11 (34) | 0.394 |
| Pattern of recurrence |  |  | 0.628 |
| Local/regional | 5 (9) | 5 (16) |
| Distant | 6 (10) | 5 (16) |
| Local and distant | 2 (3) | 1 (3) |
| Adjuvant chemotherapy | 12 (21) | 8 (25) | 0.502 |

ASA: American Society of Anesthesiology; CCI: Charlson Comorbidity Index; BMI: Body mass index.

**Table 3 Types of surgeries performed in surgically treated patients of the study group, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Type of surgery** | **IGBC (*n* = 58)** | **NIGBC (*n* = 32)** | **Total number (*n* = 90)** |
| Radical cholecystectomy | 0 | 18 (56) | 18 (20) |
| Radical cholecystectomy +extrahepatic bile duct excision | 0 | 6 (19) | 6 (7) |
| Gallbladder bed resection | 36 (62) | 0 | 36 (40) |
| Gallbladder bed resection + extrahepatic bile duct excision | 17 (30) | 0 | 17 (19) |
| Segment IVb + V liver resection | 2 (3) | 0 | 2 (2) |
| Extrahepatic bile duct excision | 2 (3) | 0 | 2 (2) |
| **Extended resections:** |  |  | 4 (4) |
| Central hepatectomy + caudate lobe resection + extrahepatic bile duct excision | 0 | 1 (3) | 1 (1) |
| Pancreaticoduodenectomy + Gallbladder bed resection + right hemicolectomy | 0 | 1 (3) |  |
| Pancreaticoduodenectomy + right hepatectomy | 0 | 1 (3) |  |
| Radical cholecystectomy + right hemicolectomy + partial gastrectomy | 0 | 1 (3) |  |

Portal lymphadenectomy performed in all cases.

**Table 4 Cox proportional hazard analysis for overall survival**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | ***P* value** | **HR (95%CI)** | ***P* value** | **HR (95%CI)** | ***P* value** | **HR (95%CI)** |
|  | **Univariable analysis** | | **Multivariable analysis** | | **Multivariable analysis (excluding timing of diagnosis variable)** | |
| Age | **0.011** | 1.04 (1.01-1.07) | 0.453 | 1.02 (0.97-1.08) | 0.153 | 1.04 (0.99-1.10) |
| Gender | 0.96 | 1.01 (0.71-1.44) | - | - | - | - |
| Race | 0.853 | 1.05 (0.61-1.81) | - | - | - | - |
| BMI | 0.601 | 0.983 (0.92-1.05) | - | - | - | - |
| ASA score | **0.024** | 1.96 (1.09-3.52) | 0.121 | 2.26 (0.81-6.31) | 0.061 | 2.53 (0.96-6.66) |
| CCI score | 0.064 | 1.19 (0.99-1.42) | 0.66 | 0.91 (0.58-1.41) | 0.269 | 0.78 (0.50-1.21) |
| T stage | **< 0.001** | 2.73 (1.72-4.34) | 0.913 | 1.04 (0.56-1.90) | 0.088 | 1.62 (0.93-2.81) |
| N stage | **< 0.001** | 5.65 (2.84-11.25) | **< 0.001** | 3.07 (1.72-5.46) | **0.001** | 3.59 (1.72-7.49) |
| R status | **< 0.001** | 7.35 (3.38-15.95) | **< 0.001** | 5.26 (2.10-13.13) | **0.012** | 3.00 (1.27-7.07) |
| Post-operative complications | 0.885 | 1.05 (0.53-2.09) | - | - | - | - |
| Non-incidental diagnosis | **0.004** | 2.41 (1.32-4.38) | **0.026** | 2.25 (1.10-4.58) | **Not included in analysis** | **Not included in analysis** |
| Degree of differentiation | 0.443 | 1.40 (0.61-3.21) | *-* | - | - | - |
| Adjuvant chemotherapy | 0.87 | 1.07 (0.47-2.44) | - | - | - | - |

ASA: American Society of Anesthesiology; CCI: Charlson Comorbidity Index; BMI: Body mass index.

**Table 5 Cox proportional hazard analysis for disease free survival**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | ***P* value** | **HR (95%CI)** | ***P* value** | **HR (95%CI)** | ***P* value** | **HR (95%CI)** |
|  | **Univariable analysis** | | **Multivariable analysis** | | **Multivariable analysis (excluding timing of diagnosis variable)** | |
| Age | 0.275 | 1.02 (0.98-1.06) | - | - | - | - |
| Gender | 0.732 | 0.85 (0.34-2.13) | - | - | - | - |
| Race | 0.997 | 1.13 (0.15-8.51) | - | - | - | - |
| BMI | 0.782 | 0.99 (0.91-1.07) | - | - | - | - |
| ASA score | 0.817 | 0.91 (0.42-1.98) | - | - | - | - |
| CCI score | 0.842 | 0.98 (0.76-1.26) | - | - | - | - |
| T stage | **0.021** | 2.06 (1.12-3.82) | 0.504 | 1.26 (0.64-2.47) | 0.21 | 1.53 (0.79-2.97) |
| N stage | **0.001** | 4.08 (1.83-9.08) | **0.006** | 3.18 (1.39-7.26) | **0.008** | 3.08 (1.35-7.06) |
| R status | **< 0.001** | 11.05 (3.31-36.94) | **0.006** | 5.76 (1.67-19.88) | **0.002** | 6.95 (1.98-24.34) |
| Post-operative complications | 0.404 | 0.63 (0.22-1.85) | **-** | - | - | - |
| Non-incidental diagnosis | **0.011** | 2.78 (1.26-6.12) | 0.09 | 2.13 (0.89-5.09) | **Not included in analysis** | **Not included in analysis** |
| Degree of differentiation | 0.211 | 0.65 (0.33-1.28) | *-* | - | - | - |
| Adjuvant chemotherapy | 0.457 | 1.42 (0.56-3.58) | - | - | - | - |

ASA: American Society of Anesthesiology; CCI: Charlson Comorbidity Index; BMI: Body mass index.